RediTrex Now Available for RA, pJIA, Psoriasis Treatment

RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.

RediTrex®, a preservative-free, single-dose prefilled syringe that delivers methotrexate, has been made available by Cumberland Pharmaceuticals.

RediTrex is approved for the management of patients with severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy. It is also indicated for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.

The product, which was specifically designed for patients with limited dexterity, is supplied in the following dosage strengths: 7.5mg, 10mg, 12.5mg, 15mg, 17.5mg, 20mg, 22.5mg and 25mg. Each dose is color-coded to reduce the potential for dosing errors.

RediTrex is administered as a once-weekly subcutaneous injection; for patients who require alternative dosing (doses <7.5mg per week or doses >25mg per week; high-dose regimens, or dose adjustments of <2.5mg increments), another formulation of methotrexate should be used.

“The RediTrex product line offers patients an important new choice in convenience, safety and dosing accuracy for their methotrexate therapy,” said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. 

For more information visit


Introducing RediTrex®, a new methotrexate delivery system. [press release]. Nashville, TN: PRNewswire; November 17, 2020.

This article originally appeared on MPR